TO · SZLS.TO
StageZero Life Sciences Ltd.
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- Richmond Hill, ON L4B 3B2
- Website
- stagezerolifesciences.com
Price · as of 2022-12-31
$0.04
Market cap 4.94M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $57.90 | +144,650% |
| Intrinsic Value(DCF) | $0.15 | +275% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $2.60 | +6,400% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2008 | $6.97 | $83.96 | $0.00 | $0.00 | $445.00 |
| 2009 | $13.05 | $572.53 | $0.00 | $0.00 | $0.00 |
| 2010 | $8.55 | $587.08 | $0.00 | $0.00 | $307.20 |
| 2011 | $10.57 | $36.36 | $0.00 | $0.00 | $126.40 |
| 2012 | $5.92 | $93.81 | $0.13 | $0.00 | $0.00 |
| 2013 | $10.40 | $33.30 | $0.00 | $0.00 | $131.50 |
| 2014 | $6.96 | $441.96 | $142.47 | $0.00 | $0.00 |
| 2015 | $1.04 | $38.74 | $0.00 | $0.00 | $91.60 |
| 2016 | $2.88 | $90.59 | $14,647.55 | $0.00 | $0.00 |
| 2017 | $1.08 | $41.08 | $0.00 | $0.00 | $17.10 |
| 2018 | $1.24 | $43.69 | $0.00 | $0.00 | $14.30 |
| 2019 | $0.32 | $35.28 | $0.00 | $0.00 | $2.90 |
| 2020 | $1.28 | $596.50 | $24.69 | $0.00 | $0.00 |
| 2021 | $0.19 | $33.95 | $7.73 | $0.00 | $0.00 |
| 2022 | $0.12 | $41.46 | $3.24 | $0.00 | $2.60 |
AI valuation
Our deep-learning model estimates StageZero Life Sciences Ltd.'s (SZLS.TO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $57.90
- Current price
- $0.04
- AI upside
- +144,650%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.15
+275% upside
Graham-Dodd
—
— upside
Graham Formula
$2.60
+6,400% upside
About StageZero Life Sciences Ltd.
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in the United States and Canada. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is Aristotle, a multi-cancer panel test for simultaneously screening for various cancers from a single sample of blood with high sensitivity and specificity for each cancer. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; COVID polymerase chain reaction testing and blood test analysis; Prostate Health Index, a screening test for prostate cancer; and BreastSentry, a test to determine a woman's risk for developing breast cancer. The company was founded in 1998 and is headquartered in Richmond Hill, Canada.
- CEO
- James R. Howard-Tripp
- Employees
- 40
- Beta
- 0.45
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.15 ÷ $0.04) − 1 = +275% (DCF, example).